Cargando…
Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic
AIMS: Fabry disease (FD) is a rare X‐linked genetic disorder caused by α‐galactosidase A (AGALA) deficiency. Whereas ‘classic’ variant has multisystemic manifestation, the more recently described ‘later‐onset’ variant is characterized by predominant cardiac involvement that often mimics hypertrophic...
Autores principales: | Zemánek, David, Januška, Jaroslav, Honěk, Tomáš, Čurila, Karol, Kubánek, Miloš, Šindelářová, Štěpánka, Zahálková, Lucie, Klofáč, Petr, Laštůvková, Eliška, Lichnerová, Eva, Aiglová, Renata, Lhotský, Jan, Vondrák, Jiří, Dostálová, Gabriela, Táborský, Miloš, Kasper, David, Linhart, Aleš |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773751/ https://www.ncbi.nlm.nih.gov/pubmed/36087038 http://dx.doi.org/10.1002/ehf2.14135 |
Ejemplares similares
-
Trends in the treatment and survival of heart failure patients: a nationwide population‐based study in the Czech Republic
por: Táborský, Milos, et al.
Publicado: (2021) -
Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease
por: Rob, Daniel, et al.
Publicado: (2016) -
Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations
por: Rob, Daniel, et al.
Publicado: (2022) -
Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease
por: Rob, Daniel, et al.
Publicado: (2017) -
Ventricular tachycardia: a presentation of Fabry disease case report
por: Pavlu, Ludek, et al.
Publicado: (2018)